-
The listing application of Huiyu Pharmaceutical's Class 4 generic drug Octreotide Acetate Injection has entered the stage of administrative approval
Time of Update: 2022-04-17
com, the terminal sales of this product in China's public medical institutions will exceed 2 billion yuan in 2020.
Application of Consistency Evaluation of Octreotide Acetate Injection (including new classification report) Source: Minet.
-
Nanjing Chia Tai Tianqing to win $1.5 billion extended-release tablets
Time of Update: 2022-04-17
Recently, Nanjing Chia Tai Tianqing entered the administrative approval stage with Mirabegron extended-release tablets, which are imitated Category 4, and is expected to be approved for marketing in the near future .
-
AI-assisted development of "old drug new use" approved by FDA
Time of Update: 2022-04-17
S. Food and Drug Administration (FDA) has approved Igalmi (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I/II disorder .
Retrieved April 6, 2022, from https:// news-release/2022/04/06/2417422/0/en/BioXcel-Therapeutics-Announces-FDA-Approval-of-IGALMI-dexmedetomidine-Sublingual-Film-for-Acute-Treatment-of-Agitation-Associated-with- Schizophrenia-or-Bipolar-I-or-II-Disorder-in-.
-
Qilu's first over 100 million antihypertensive drug appraised the first domestically produced $1 billion variety
Time of Update: 2022-04-17
Recently, Qilu Pharmaceutical has made new progress in the field of hypertension medication: carvedilol tablets have been successfully reviewed, the first in China, and the sales of this product in China's public medical institutions will exceed 100 million yuan in 2020; Riociguat tablets reported It is the first domestically produced drug, and currently no generic drugs have been approved in China .
-
Who is the "pillar" for the sales growth rate of big pharmaceutical companies?
Time of Update: 2022-04-17
Recently, large multinational pharmaceutical companies have successively released their 2021 annual reports.
How is the growth of large pharmaceutical companies?
(Data sources: Annual reports of various companies, Huachuang Securities, Medical Cube, etc.
-
Local pharmaceutical companies launch innovative drugs overseas, and welcome new progress!
Time of Update: 2022-04-17
Recently, BeiGene announced that the Marketing Authorization Application (MAA) of its self-developed PD-1 monoclonal antibody Baizean® (generic name: Tislelizumab injection) was officially accepted by the European Medicines Agency (EMA).
-
In April, the variety of generic drugs of many pharmaceutical companies announced good news, and passed the consistency evaluation!
Time of Update: 2022-04-17
Haisco: Arginine Glutamate Injection Review On April 2, Haisco announced that Liaoning Haisco Pharmaceutical, a wholly-owned subsidiary of the company, has recently received the "Approval for Supplementary Drug Application" issued by the State Drug Administration.
-
Under the constant pressure of pharmaceutical companies, a large number of drugs are withdrawing from the medical insurance catalog
Time of Update: 2022-04-17
drug Guhong Injection will withdraw from the Anhui Provincial Medical Insurance Catalogue on December 31, 2022 .
In addition to Guhong injection, in recent years, Buchang Pharmaceutical has a number of drugs that have been withdrawn from medical insurance in many places .
-
Over 3 billion!
Time of Update: 2022-04-17
Sources of varieties that Simcere Pharmaceuticals intends to include in the seventh batch: Among the varieties under review by Minet database and Shanghai Sunshine Pharmaceutical Purchasing Network (excluding withdrawn or unapproved varieties), 3 varieties submitted supplementary applications for consistency evaluation; 11 varieties are reported for production under the new classification, and 3 of them have not been approved for the first imitation (including the first imitation of the dosage form) .
-
5 pharmaceutical companies have 6 product regulations, and the listing application has not been approved!
Time of Update: 2022-04-17
According to the data query of the State Food and Drug Administration, there are currently 25 approval numbers for octreotide acetate injection in China, involving pharmaceutical companies such as Renfu Pharmaceutical and Sinopharm Yixin .
-
Reduce postprandial hyperglycemia!
Time of Update: 2022-04-17
Recently, Zhejiang Medicine entered the administrative examination and approval stage with the miglitol orally disintegrating tablet, which was produced as a generic version of Class 3, and this product is temporarily blank in the domestic market .
-
With the continuous expansion of the traditional Chinese medicine formula granule market, improving the mechanization capability will be crucial
Time of Update: 2022-04-17
The industry believes that with the expansion of hospitals and medical insurance coverage, the market of traditional Chinese medicine formula granules is expected to continue to grow .
-
The pivotal Phase 3 clinical results of IL-2 receptor targeted therapy are positive, and the marketing application is expected to be submitted this year
Time of Update: 2022-04-17
Today, Citius Pharmaceuticals announced positive top-line results from a pivotal Phase 3 clinical trial of its investigational therapy I/ONTAK (E7777) in patients with persistent or relapsed cutaneous T-cell lymphoma (CTCL) .
-
The State Food and Drug Administration has approved 24 new coronavirus antigen detection reagents
Time of Update: 2022-04-17
As of April 2, the State Food and Drug Administration has approved 24 new coronavirus antigen detection reagent products .
Attachment: New coronavirus antigen detection reagents approved by the State Food and Drug Administration
-
PD-1 products continue to be launched, and the "involution" of related pharmaceutical companies will continue to intensify
Time of Update: 2022-04-17
When evaluating the sales performance of PD-1 in the annual report, Junshi Bio said that although the sales volume in 2021 has increased, it has failed to achieve "price-for-volume", resulting in negative growth in sales revenue .
-
Multinational pharmaceutical companies accelerate "slimming", and another pharmaceutical company sells its business in China
Time of Update: 2022-04-17
It is reported that after the completion of this transaction, YaoPharma will obtain 100% equity of Daiichi Sankyo Pharmaceutical (Beijing) and the product rights of Colabituto tablets and injections in mainland China .
-
77 varieties withdraw from the net!
Time of Update: 2022-04-17
Oncology drugs that have applied for withdrawal from the network in Shanxi Province, such as CSK's lapatinib tosylate tablets (Tailisha), which is mainly used to treat breast cancer, entered the Chinese market in 2013 and achieved global sales of US$4 million However, with the end of the patent period, the influx of generic drugs from many companies including Hengrui and Kelun has brought an impact on the performance of the original research products .
-
Kelun Pharmaceutical's Compound Amino Acid (15) Dipeptide (2) Injection was approved as an innovative drug for clinical trials
Time of Update: 2022-04-17
On February 21, the official website of the State Food and Drug Administration showed that Sichuan Kelun Pharmaceutical's compound amino acid (15) dipeptide (2) injection was approved and reviewed as a supplementary application, and it was the first company to review the product .
-
Shows long-term efficacy!
Time of Update: 2022-04-17
The long-acting C5 complement inhibitor Ultomiris (ravulizumab) showed long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life during 60 weeks of treatment .
-
just!
Time of Update: 2022-04-16
The competitive landscape of blood products is changing Open the prelude to the collection of biosimilar drugs Such a situation is a big challenge for Roche: In 2021, Roche's pharmaceutical business in China will generate US$3.
